Eli Lilly and Company

Uniting caring with discovery to create medicines that make life better worldwide. Lilly’s official account (formerly LillyPad) 

[Eli Lilly and Company @EliLillyandCo]

Thank you for reaching out to us, we are here to help. If you require emergency assistance, please seek help from a doctor. Due to the nature of our highly regulated industry, we are unable to discuss certain topics here. Please call the Lilly Answer Center at 1-800-Lilly-Rx to connect with us.

[Eli Lilly and Company @EliLillyandCo]

@hasinakathrada We appreciate you reaching out, @hasinakathrada. In our highly regulated industry, we are not to discuss some topics via social media. Connect with Lilly South Africa about concerns or questions via email: [email protected].

[Eli Lilly and Company @EliLillyandCo]

@matthewcondello Hi Matthew. Thank you for your question. To learn more about this medicine, including treatment details and patient resources, please follow the link and select the logo of your medicine to learn more: https://t.co/ZZXNZMLx1F

[Eli Lilly and Company @EliLillyandCo]

@amuguneAG Thank you for reaching out to us. As a pharmaceutical company, we are unable to provide individual medical advice. We recommend you speak with your health care professional as they are best placed to assess medical conditions and provide advice and treatment options.

[Eli Lilly and Company @EliLillyandCo]

🎉 That’s a wrap on ADA 2026. The data showed the potential for advancements in obesity and type 2 diabetes treatments. Our work continues from here, focusing on something important for patients: Choices🎉 That’s a wrap on ADA 2026. The data showed the potential for advancements in obesity and type 2 diabetes treatments. Our work continues from here, focusing on something important for patients: Choices🎉 That’s a wrap on ADA 2026. The data showed the potential for advancements in obesity and type 2 diabetes treatments. Our work continues from here, focusing on something important for patients: Choices🎉 That’s a wrap on ADA 2026. The data showed the potential for advancements in obesity and type 2 diabetes treatments. Our work continues from here, focusing on something important for patients: Choices🎉 That’s a wrap on ADA 2026. The data showed the potential for advancements in obesity and type 2 diabetes treatments. Our work continues from here, focusing on something important for patients: Choices🎉 That’s a wrap on ADA 2026. The data showed the potential for advancements in obesity and type 2 diabetes treatments. Our work continues from here, focusing on something important for patients: Choices.

[Eli Lilly and Company @EliLillyandCo]

We appreciate you checking. You might try browsing our listing of research areas to see if Lilly is conducting clinical trials in your area of interest: https://t.co/wBuGAi2CZC. If you don’t find what you are looking for there, you may find more information on https://t.co/bPNLc065J8.

[Eli Lilly and Company @EliLillyandCo]

🚨 Our investigational triple agonist helped people lose weight, but that’s not all according to data shared at ADA 2026. See more about the obesity-related conditions it helped in our study.

[Eli Lilly and Company @EliLillyandCo]

A new pathway for access to obesity treatment through Medicare begins July 1. Eligible Medicare Part D patients may be able to get certain medicines for weight management through Medicare GLP-1 Bridge.

Learn more and see the CMS Medicare GLP-1 Bridge Clinical Criteria: https://t.co/IwCiQnl9Q9

[Eli Lilly and Company @EliLillyandCo]

If this is an emergency, seek help from a doctor as soon as possible. In our highly regulated industry, we are unable to discuss some topics via social media.

For adverse events or side effects, please contact Lilly Middle East at: [email protected]

For product complaints and questions, please contact Lilly Middle East at: [email protected]

[Eli Lilly and Company @EliLillyandCo]

Hello Kat, Thank you for reaching out to us, we are here to help. If you require emergency assistance, please seek help from a doctor. Due to the nature of our highly regulated industry, we are unable to discuss certain topics here. Please call the Lilly Answer Center at 1-800-Lilly-Rx or reach us HERE https://t.co/TVeEbxPUaS if you are unable to call.

[Eli Lilly and Company @EliLillyandCo]

@TK1STYLE Hello. Your question is important, thank you for contacting Lilly. Due to the nature of our highly regulated industry, we are unable to discuss certain topics here. Please call the Lilly Answer Center at 1-800-Lilly-Rx to connect with us.

[Eli Lilly and Company @EliLillyandCo]

In a late-breaking oral presentation, Lilly shared Phase 3 study results for one of our medicines as part of a time-limited regimen in chronic lymphocytic leukemia (#CLL).

Learn more here: https://t.co/tIp1skLgXe

[Eli Lilly and Company @EliLillyandCo]

In an oral presentation at #EHA2026, initial clinical results will be shared from a Phase 1 study evaluating a first-in-class therapy in previously treated myelofibrosis.

Learn more here: https://t.co/3ylZ3ZWTrr

[Eli Lilly and Company @EliLillyandCo]

@MrsZepboundJP Thank you for sharing your experience. We deeply value the unique perspectives and journeys of individuals like you, and we invite you to explore our Your Story Matters page and share more if interested: https://t.co/iIvNPepyzm.

[Eli Lilly and Company @EliLillyandCo]

NEW Phase 3 data today at #ADA2026: Lilly's investigational triple agonist met all primary endpoints in TRIUMPH-1. Patients on the 12 mg dose lost an avg of 70 pounds (28.3%) over 80 weeks. Read more: https://t.co/NCnsqwktI7

[Eli Lilly and Company @EliLillyandCo]

@biglurp Thanks for reaching out. To find a Lilly clinical trial near you, search by medical condition and ZIP code on https://t.co/bxJlj4frFf or call 1-800-545-5979 for assistance. You might also try https://t.co/Rj4MHnQ4TL. Best of luck in your search.

[Eli Lilly and Company @EliLillyandCo]

@biglurp 🏆 Our oral GLP-1 is on track for type 2 diabetes submission in the U.S. See how it performed in three type 2 diabetes trials, including a head-to-head against another oral GLP-1. https://t.co/vNd85rAZjB Reply #stop to opt-out.

[Eli Lilly and Company @EliLillyandCo]

The @US_FDA has approved a new dosing option for Lilly’s moderate-to-severe atopic dermatitis (#eczema) treatment. Learn more about what this may mean for patients: https://t.co/JHc16JSo5u

[Eli Lilly and Company @EliLillyandCo]

That’s a wrap on #ADA2026. It left us with important reminders about why science matters and who it’s for. #WeAreLilly

[Eli Lilly and Company @EliLillyandCo]

@Momecann Dear @Momecann,

Thank you for your question. To learn more about this medicine, including treatment details and patient resources, please follow the link and select the logo of your medicine to learn more: https://t.co/ZZXNZMLx1F

[Eli Lilly and Company @EliLillyandCo]

New data: Our oral GLP-1 delivered superior A1C control and weight loss across three clinical trials. Read more: https://t.co/GuyV2Jv4iE #ADA2026

[Eli Lilly and Company @EliLillyandCo]

Menopause makes weight loss harder. But post-hoc analyses from two clinical studies of one of our obesity medicines showed what could be possible. Up to 5 in 10 women in one study experienced ≥15% weight loss on the highest dose at 72 weeks. Read more: https://t.co/ThlAOFvGQi

[Eli Lilly and Company @EliLillyandCo]

Women at every stage of menopause — pre, peri and post — experienced meaningful weight loss in post-hoc analyses of two studies of one of our obesity medicines presented at #ADA2026. Up to 30 pounds lost on the highest dose at 72 weeks. Read more: https://t.co/fIN9XL7ssZ

[Eli Lilly and Company @EliLillyandCo]

The conversations at #ADA2026 are helping to build a new era of care.